[go: up one dir, main page]

SV2003001053A - Composicion liquida farmaceutica ref. pc21501 - Google Patents

Composicion liquida farmaceutica ref. pc21501

Info

Publication number
SV2003001053A
SV2003001053A SV2002001053A SV2002001053A SV2003001053A SV 2003001053 A SV2003001053 A SV 2003001053A SV 2002001053 A SV2002001053 A SV 2002001053A SV 2002001053 A SV2002001053 A SV 2002001053A SV 2003001053 A SV2003001053 A SV 2003001053A
Authority
SV
El Salvador
Prior art keywords
pain
approximately
component
methods
gaba analog
Prior art date
Application number
SV2002001053A
Other languages
English (en)
Inventor
Neema Mahesh Kulkarni
Michael Schneider
Steven Bernard Silberg
Hans Richard Meyer-Wonnay
Nahid Sanii-Yahyai
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2003001053(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of SV2003001053A publication Critical patent/SV2003001053A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

SE DESCRIBE UNA COMPOSICION FARMACEUTICA LIQUIDA DE UN ANALOGO DE GABA QUE COMPRENDE AL MENOS UN ALCOHOL POLIHIDROXILICO QUE CONTIENE DE 2 A 6 ATOMOS DE CARBONO, QUE TIENE UN PH DESDE APROXIMADAMENTE 5,5 A APROXIMADAMENTE 7,0, Y ADEMAS UNA COMPOSICION FARMACEUTICA LIQUIDA EN DOS COMPONENTES QUE COMPRENDE UN PRIMER COMPONENTE QUE COMPRENDE UNA MEZCLA EN POLVO QUE COMPRENDE UN ANALOGO DE GABA Y UN ALCOHOL POLIHIDROXILICO SOLIDO, Y UN SEGUNDO COMPONENTE QUE COMPRENDE UN ABASE LIQUIDA, ASI COMO METODOS PARA PREPARAR LAS COMPOSICIONES Y UN METODO PARA TRATAR ENFERMEDADES CEREBRALES, INCLUYENDO EPILEPSIA, ATAQUES DE DESFALLECIMIENTO, HIPOQUINESIA Y TRAUMATISMO CRANEALES, TRASTORNOS NEURODEGENERATIVOS, DEPRESION, MANIA Y TRASTORNOS BIPOLARES, ANSIEDAD, PANICO, INFLAMACION, COLICO RENAL, INSOMNIO, TRASTORNOS GASTROINTESTINALES, INCONTINENCIA, DOLOR, INCLUYENDO DOLOR NEUROPATICO, DOLOR MUSCULAR, DOLORESQUELTICO Y MIGRAÑA, UTILIZANDO UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE LAS COMPOSICIONES FARMACEUTICAS
SV2002001053A 2001-05-25 2002-05-24 Composicion liquida farmaceutica ref. pc21501 SV2003001053A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29383201P 2001-05-25 2001-05-25
US34373301P 2001-10-25 2001-10-25

Publications (1)

Publication Number Publication Date
SV2003001053A true SV2003001053A (es) 2003-03-18

Family

ID=26968180

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2002001053A SV2003001053A (es) 2001-05-25 2002-05-24 Composicion liquida farmaceutica ref. pc21501

Country Status (43)

Country Link
US (2) US20020198261A1 (es)
EP (1) EP1395242B1 (es)
JP (1) JP2004534764A (es)
KR (1) KR100582963B1 (es)
CN (1) CN100346779C (es)
AP (1) AP1815A (es)
AR (1) AR033922A1 (es)
AT (1) ATE334656T1 (es)
AU (1) AU2002258026B2 (es)
BG (1) BG108376A (es)
BR (1) BR0209973A (es)
CA (1) CA2446574C (es)
CR (1) CR7150A (es)
CY (1) CY1105147T1 (es)
CZ (1) CZ299755B6 (es)
DE (1) DE60213592T2 (es)
DK (1) DK1395242T3 (es)
DO (1) DOP2002000403A (es)
EA (1) EA008087B1 (es)
EE (1) EE200300587A (es)
EG (1) EG24078A (es)
ES (1) ES2265040T3 (es)
GE (1) GEP20053620B (es)
HR (1) HRP20030833B1 (es)
HU (1) HUP0401366A2 (es)
IL (1) IL158359A0 (es)
IS (1) IS2428B (es)
MA (1) MA27026A1 (es)
MX (1) MXPA03009392A (es)
MY (1) MY128615A (es)
NO (1) NO20035200D0 (es)
NZ (1) NZ529173A (es)
OA (1) OA12604A (es)
PA (1) PA8545901A1 (es)
PE (1) PE20030087A1 (es)
PL (1) PL366384A1 (es)
PT (1) PT1395242E (es)
RS (1) RS87203A (es)
SI (1) SI1395242T1 (es)
SK (1) SK286227B6 (es)
SV (1) SV2003001053A (es)
WO (1) WO2002094220A1 (es)
ZA (1) ZA200308393B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2003250481A1 (en) * 2002-08-15 2004-03-03 Pfizer Inc. Therapeutic use of fused bicyclic or tricyclic amino acids
RU2353358C2 (ru) * 2002-12-13 2009-04-27 Уорнер-Ламберт Компани Ллс Производные прегабалина для лечения приливов
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
WO2005025675A1 (en) * 2003-09-12 2005-03-24 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
EP1680144B1 (en) * 2003-10-08 2011-10-05 Mallinckrodt LLC Methylphenidate solution and associated methods of administration and production
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102004015752B4 (de) * 2004-03-31 2007-04-05 Christian-Albrechts-Universität Zu Kiel Verwendung von Gabapentin-Laktam zur Behandlung renaler Erkrankungen
KR100870381B1 (ko) * 2004-10-14 2008-11-25 다이킨 고교 가부시키가이샤 분위기개변방법, 그리고 이에 이용되는 분무제 및 분무장치
CA2618481A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for treating alzheimer's disease
EP1915353A2 (de) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Isophthalsäurediamide zur behandlung der alzheimer erkrankung
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
EP2116618A1 (en) * 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) * 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
WO2015144825A1 (en) * 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
CN104940930A (zh) * 2015-05-31 2015-09-30 黑龙江佰彤儿童药物研究有限公司 一种治疗儿童癫痫药物口服乳剂及其制备方法
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
EP3668508A1 (en) 2017-08-19 2020-06-24 FTF Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
CN112566625A (zh) * 2018-08-18 2021-03-26 夫特弗制药私人有限公司 口服剂量的化学治疗药物悬浮液
GB2591396B (en) 2018-08-18 2023-06-07 Ftf Pharma Private Ltd Pharmaceutical suspension for oral dosage
US20220175707A1 (en) 2019-03-26 2022-06-09 Orion Corporation Pregabalin formulations and use thereof
HU231397B1 (hu) 2021-01-22 2023-06-28 Egis Gyógyszergyár Zrt. Pregabalint tartalmazó topikális gyógyszerkészítmény
CA3208954A1 (en) 2021-01-22 2022-07-28 Egis Gyogyszergyar Zrt. Topical formulation containing modified phospholipid compounds
WO2022168968A1 (ja) * 2021-02-05 2022-08-11 学校法人近畿大学 末梢神経障害の予防又は改善剤
EP4395758A4 (en) * 2021-08-31 2025-07-30 Avion Pharmaceuticals Llc STABLE GABAPENTIN POWDER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
CN1303991C (zh) * 1998-05-15 2007-03-14 沃尼尔·朗伯公司 γ-氨基丁酸衍生物的稳定药物制剂和其制备方法
PL365927A1 (en) * 2000-11-30 2005-01-10 Pfizer Products Inc. Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Also Published As

Publication number Publication date
CZ20033066A3 (cs) 2004-08-18
BR0209973A (pt) 2004-04-06
SI1395242T1 (en) 2006-10-31
RS87203A (sr) 2006-10-27
GEP20053620B (en) 2005-09-26
CA2446574A1 (en) 2002-11-28
DOP2002000403A (es) 2002-11-30
MXPA03009392A (es) 2004-01-29
PT1395242E (pt) 2006-11-30
AP1815A (en) 2008-01-04
MA27026A1 (fr) 2004-12-20
JP2004534764A (ja) 2004-11-18
PA8545901A1 (es) 2003-09-05
EP1395242A1 (en) 2004-03-10
IS6986A (is) 2003-10-09
EG24078A (en) 2008-05-11
CA2446574C (en) 2008-04-01
CN1509165A (zh) 2004-06-30
MY128615A (en) 2007-02-28
ATE334656T1 (de) 2006-08-15
US7256216B2 (en) 2007-08-14
AP2003002907A0 (en) 2003-12-31
CZ299755B6 (cs) 2008-11-12
KR20040003006A (ko) 2004-01-07
IL158359A0 (en) 2004-05-12
EP1395242B1 (en) 2006-08-02
PL366384A1 (en) 2005-01-24
BG108376A (bg) 2005-04-30
HUP0401366A2 (hu) 2004-11-29
ES2265040T3 (es) 2007-02-01
IS2428B (is) 2008-10-15
HRP20030833B1 (en) 2007-04-30
CR7150A (es) 2004-02-23
US20020198261A1 (en) 2002-12-26
DK1395242T3 (da) 2006-10-30
EA008087B1 (ru) 2007-02-27
ZA200308393B (en) 2005-04-26
EA200301152A1 (ru) 2004-04-29
SK286227B6 (sk) 2008-05-06
US20040072904A1 (en) 2004-04-15
CN100346779C (zh) 2007-11-07
HRP20030833A2 (en) 2004-08-31
DE60213592D1 (de) 2006-09-14
KR100582963B1 (ko) 2006-05-24
PE20030087A1 (es) 2003-02-14
AU2002258026B2 (en) 2007-08-02
EE200300587A (et) 2004-02-16
NO20035200L (no) 2003-11-24
HK1062646A1 (zh) 2004-11-19
DE60213592T2 (de) 2007-08-09
SK14112003A3 (sk) 2004-08-03
CY1105147T1 (el) 2010-03-03
NZ529173A (en) 2005-07-29
OA12604A (en) 2006-06-08
WO2002094220A1 (en) 2002-11-28
AR033922A1 (es) 2004-01-07
NO20035200D0 (no) 2003-11-24

Similar Documents

Publication Publication Date Title
SV2003001053A (es) Composicion liquida farmaceutica ref. pc21501
EP1674107A8 (en) Use of daptomycin
PL364174A1 (en) Fibrate-statin combinations with reduced fed-fasted effects
RU2008136408A (ru) Фармацевтическая композиция
BR9912179A (pt) Composição neuroprotetora para a prevenção e/ou tratamento de alterações nervosas e do comportamento devido a estados de ansiedade ou depressão
US20250195409A1 (en) Methods for improving cutaneous permeation of cannabinoids and fatty acid amides
UY25513A1 (es) Composiciones sólidas que contienen gabapentina y proceso para su preparación
RU2004110041A (ru) Фармацевтическая композиция, содержащая габапентин или его аналог и альфа-аминоамид, и ее применение в качестве анальгетика
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
WO2004078147A3 (en) Oxytocin controlled release formulations and methods of using same
AR029646A1 (es) Combinacion sinergistica que comprende cantidades efectivas de un antagonista de receptor de nk1 y un analogo de gaba, composiciones farmaceuticas de la misma y uso de dicha composicion
JP5271473B2 (ja) 神経障害性疼痛ならびに群発性頭痛および偏頭痛に関連する疼痛の予防もしくは治療における使用のためのカルバメート化合物
ATE242200T1 (de) Valnoctamid-stereoisomere, eine methode zu ihrer herstellung und abtrennung und ihre anwendungen
UA89753C2 (ru) Применение модафинила и антидепрессанта при лечении депрессии и для сокращения времени до начала действия антидепрессанта
ATE289583T1 (de) Stereoisomere von propyl-isopropylacetamid, verfahren zu deren herstellung sowie diese enthaltende pharmazeutische zubereitungen
ECSP034853A (es) Composición farmacéutica líquida
BRPI0409170A (pt) combinações compreendendo drogas antiepilépticas para o tratamento de distúrbios neurológicos
WO2001080845A3 (en) (2-aminoethyl) oxime derivatives for the treatment of depression
UY27310A1 (es) Composición farmacéutica líquida
RS50948B (sr) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju neuropatskog bola
WO2020168337A4 (en) Compositions and methods for treatment of depression and other disorders
AR023657A1 (es) Composicion, usos de la misma, formulacion farmaceutica, proceso para la preparacion de la composicion y kit
UY26406A1 (es) Aminoácidos bicíclicos como agentes farmacéuticos
BRPI0416691A (pt) forma de preparação farmacêutica sólida
UA41974C2 (uk) Терапевтична протизапальна та аналгетична фармацевтична композиція для місцевого трансдермального застосування, що містить nimesulide (варіанти), та спосіб її одержання

Legal Events

Date Code Title Description
FC Refusal